Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 2, 2009, Pages 155-157

  Goedecke, Vega A ^a   Clajus, Christian ^a   Burkhardt, Olaf ^b   Martens Lobenhoffer, Jens ^c   Bode Böger, Stefanie M ^c   Kielstein, Jan T ^a   Hiss, Marcus ^a  

^a Division of Nephrology and Hypertension   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DAPTOMYCIN; PROCALCITONIN;

ADULT; ANAMNESIS; ARTICLE; BACTERIAL COLONIZATION; CASE REPORT; CATHETER INFECTION; CELLULITIS; CLINICAL FEATURE; DIALYSATE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; PARENTERAL NUTRITION; PERITONEAL DIALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; URINE VOLUME; VANCOMYCIN RESISTANT ENTEROCOCCUS; VITAL SIGN;

AREA UNDER CURVE; DAPTOMYCIN; DIALYSIS SOLUTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 58449126961     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802613095     Document Type: Article

References (10)

1. Vargemezis, V., Pasadakis, P., Thodis, H., Coucudis, P., Peihaberis, P. Jafer, H. et al. (1989) Vancomycin therapy for Gram-positive peritonitis in patients on CAPD. Advances in Peritoneal Dialysis, 5, pp. 128-129.
2. D'Agata, EM. (2002) Antimicrobial-resistant, Gram-positive bacteria among patients undergoing chronic haemodialysis. Clin Infect Dis, 35, pp. 1212-1218.
3. Fluit, AC, Schmitz, FJ, Verhoef, J. and Milatovic, D. (2004) Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents, 24, pp. 59-66.
4. LaPlante, KL and Mermel, LA. (2007) In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant, 22, pp. 2239-2246.
5. Wise, R., Gee, T., Andrews, JM, Dvorchik, B. and Marshall, G. (2002) Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrobial Agents Chemotherapy, 46, pp. 31-33.
6. Dvorchik, B., Arbeit, RD, Chung, J., Liu, S., Knebel, W. and Kastrissios, H. (2004) Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother, 48, pp. 2799-2807.
7. Burkhardt, O., Joukhadar, C., Traunmueller, F., Hadem, J., Welte, T. and Kielstein, JT. (2008) Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. Journal of Antimicrobial Chemotherapy, 61, pp. 224-225.
8. Twardowski, ZJ, Nolph, KD, Khanna, R., Prowant, BF, Ryan, LP, Moore, HL and Nielsen, MP. (1987) Peritoneal equilibration test. Perit Dial Bull, 7, pp. 138-147.
9. Martens-Lobenhoffer, J., Kielstein, JT, Oye, C. and Bode-Boger, SM (2008) Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci
10. Hermsen, ED, Hovde, LB, Hotchkiss, JR and Rotschafer, JC. (2003) Antimicrobial increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate Model. Agents and Chemotherapy, 47, pp. 3764-3767.